# Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia

> **NCT00080496** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 430 (—)

## Conditions studied

- Bacterial Pneumonia

## Interventions

- **DRUG:** Tigecycline
- **DRUG:** Imipenem
- **DRUG:** Cilastatin

## Key facts

- **NCT ID:** NCT00080496
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 430 (—)
- **Last updated:** 2008-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080496, "Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00080496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*